| Literature DB >> 31984676 |
Vivian Delcourt1, Patrice Garcia1, Benjamin Chabot1, Benoit Loup1, Pierre Remy1, Marie-Agnès Popot1, Ludovic Bailly-Chouriberry1.
Abstract
Recombinant human erythropoietin (rHuEPO) belongs to the therapeutic class of erythropoiesis stimulating agents (ESAs) due to its implication in the creation pathway of red blood cells and thus enhancement of oxygenation. Because of this bioactivity, rHuEPO has been considered as a major doping agent in sports competitions for decades. Over the years, doping control laboratories designed several analytical strategies applied to human and animal samples to highlight any misuse. Even though multiple analytical approaches have been reported, none has yet been dedicated to racing camels. Here, we describe an analytical strategy to test camel plasma samples at screening using an ELISA assay and a targeted nano-liquid chromatography-high-resolution tandem mass spectrometry for confirmatory analysis. The method was validated and has been successfully applied to post-race samples, allowing the detection of a positive case of rHuEPO administration.Entities:
Keywords: EPO; camel race; doping control; nanoLC-HRMS/MS
Mesh:
Substances:
Year: 2020 PMID: 31984676 DOI: 10.1002/dta.2772
Source DB: PubMed Journal: Drug Test Anal ISSN: 1942-7603 Impact factor: 3.345